ARTICLE | Company News
BioChem other research news
April 10, 2000 7:00 AM UTC
BCHE will receive up to C$80 million (US$55.2 million) over 6 years from Technology Partnerships Canada to develop recombinant protein vaccines, including a meningococcal vaccine that is in Phase I te...